Diabetic Neuropathic Pain Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

The market dynamics for Diabetic Neuropathic Pain are witnessing steady growth driven by the rising prevalence of diabetes, increasing burden of neuropathic complications, growing demand for effective symptomatic therapies, and advancements in pain management approaches. Additionally, the launch of emerging therapies such as Suzetrigine (Vertex Pharmaceuticals), Pilavapadin/LX9211 (Lexicon Pharmaceuticals), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Diabetic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2034." This comprehensive report provides an in-depth understanding of Diabetic Neuropathic Pain, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Diabetic Neuropathic Pain Market

*
The market size for Diabetic Neuropathic Pain in the 7MM is expected to increase significantly during the forecast period from 2020-2034.

*
The United States accounted for the highest Diabetic Neuropathic Pain market size in 2024 among the 7MM.

*
According to the International Diabetes Federation, nearly 425 million people worldwide have diabetes.

*
Diabetic neuropathy is the most common complication of diabetes mellitus, affecting as many as 50% of patients with Type 1 and Type 2 diabetes mellitus.

*
According to Feldman et al. (2019), approximately 30-50% of patients with diabetic neuropathy develop neuropathic pain.

*
The prevalence of diabetic neuropathy, including pain, tends to increase with age and longer diabetes duration.

*
Leading Diabetic Neuropathic Pain companies, such as Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Grunenthal (Averitas Pharma), Collegium Pharmaceuticals, and others, are developing novel treatment approaches to improve pain management outcomes.

*
The promising Diabetic Neuropathic Pain therapies in clinical trials include Suzetrigine (VX-548), Pilavapadin/LX9211, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Diabetic Neuropathic Pain Market

*
Rising Prevalence of Diabetes and Associated Neuropathic Complications:The growing global burden of Type 1 and Type 2 diabetes is contributing significantly to the rise in diabetic neuropathy and neuropathic pain cases. Increasing obesity rates and aging populations are expected to further increase disease burden.

*
Increasing Demand for Effective Symptomatic Therapies:Current treatment approaches primarily focus on symptomatic pain management using anticonvulsants, antidepressants, opioids, and topical therapies. Drugs such as LYRICA (pregabalin), NUCYNTA ER (tapentadol), and QUTENZA (capsaicin) continue to play a major role in treatment practices.

*
Advancements in Emerging Non-opioid Pain Therapies:Companies are actively developing innovative therapies with novel mechanisms of action targeting pain signaling pathways. Emerging agents such as Suzetrigine and LX9211 are expected to improve efficacy and safety compared with currently available therapies.

Diabetic Neuropathic Pain Competitive Landscape

Several Diabetic Neuropathic Pain drugs in development include Suzetrigine (Vertex Pharmaceuticals), Pilavapadin/LX9211 (Lexicon Pharmaceuticals/Bristol-Myers Squibb), and others. These candidates target novel pathways involved in neuropathic pain signaling and are expected to provide improved symptomatic relief with fewer side effects.

Suzetrigine is an oral NaV1.8 inhibitor developed by Vertex Pharmaceuticals for the treatment of painful diabetic peripheral neuropathy. LX9211 is an orally administered small molecule developed by Lexicon Pharmaceuticals targeting adaptor-associated kinase 1 (AAK1) pathways involved in neuropathic pain modulation.

Discover more about therapies set to grab major Diabetic Neuropathic Pain market share @ Diabetic Neuropathic Pain Landscape [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Diabetic Neuropathic Pain Market

*
In April 2024, Vertex Pharmaceuticals announced the successful completion of an end-of-Phase II meeting with the US FDA for Suzetrigine following positive Phase II results. The company initiated a Phase III pivotal trial in patients with painful DPN.

*
In June 2024, Lexicon Pharmaceuticals published research findings from its Phase II RELIEF-DPN-1 trial investigating LX9211 for DPN pain.

*
In October 2024, Lexicon Pharmaceuticals completed screening for the PROGRESS trial evaluating LX9211 and updated the expected timeline for top-line data release.

*
In November 2024, Lexicon Pharmaceuticals completed enrollment for the multicenter Phase IIb PROGRESS trial evaluating LX9211 for the treatment of diabetic peripheral neuropathic pain.

What is Diabetic Neuropathic Pain?

Diabetic neuropathic pain is one of the most common complications associated with diabetes mellitus and significantly impacts patient quality of life. It is characterized by chronic nerve pain caused by prolonged hyperglycemia-induced nerve damage. Common symptoms include burning sensations, tingling, numbness, and sharp pain, particularly in the feet and lower extremities.

Currently, treatment remains entirely symptomatic, with no disease-modifying therapies available. Existing pharmacological approaches primarily include anticonvulsants, antidepressants, opioids, and topical agents aimed at pain reduction rather than reversal of nerve damage.

Diabetic Neuropathic Pain Epidemiology Segmentation

The Diabetic Neuropathic Pain epidemiology section provides insights into the historical and current patient pool and forecasted trends for the 7MM. The Diabetic Neuropathic Pain market report proffers epidemiological analysis for the study period 2020-2034 segmented into:

*
Total Prevalent Cases of Diabetes Mellitus

*
Total Prevalent Cases of Diabetic Neuropathy

*
Total Prevalent Cases of Diabetic Neuropathic Pain

*
Age-specific Diagnosed Prevalent Cases of Diabetic Neuropathic Pain

*
Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathic Pain

*
Total Treated Cases of Diabetic Neuropathic Pain

Scope of the Diabetic Neuropathic Pain Market Report

*
Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and emerging therapies

*
Diabetic Neuropathic Pain Market Dynamics: Key Market Forecast Assumptions of Emerging

*
Diabetic europathic Pain Drugs and Market Outlook

*
Key Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Bristol-Myers Squibb,Grunenthal (Averitas Pharma), Collegium Pharmaceuticals, and other

*
Key Therapies: Suzetrigine (VX-548), Pilavapadin/LX9211, QUTENZA, NUCYNTA ER, and others

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Diabetic Neuropathic Pain Market Access and Reimbursement

To know more about Diabetic Neuropathic Pain companies working in the treatment market, visit @ Diabetic Neuropathic Pain Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Diabetic Neuropathic Pain Market Report Introduction

*
Executive Summary for Diabetic Neuropathic Pain

*
SWOT Analysis of Diabetic Neuropathic Pain

*
Diabetic Neuropathic Pain Patient Share (%) Overview at a Glance

*
Diabetic Neuropathic Pain Market Overview at a Glance

*
Diabetic Neuropathic Pain Background and Overview

*
Diabetic Neuropathic Pain Epidemiology and Patient Population

*
Country-Specific Patient Population of Diabetic Neuropathic Pain

*
Diabetic Neuropathic Pain Current Treatment and Medical Practices

*
Diabetic Neuropathic Pain Unmet Needs

*
Diabetic Neuropathic Pain Emerging Therapies

*
Diabetic Neuropathic Pain Market Outlook

*
Country-Wise Diabetic Neuropathic Pain Market Analysis (2020-2034)

*
Diabetic Neuropathic Pain Market Access and Reimbursement of Therapies

*
Diabetic Neuropathic Pain Market Drivers

*
Diabetic Neuropathic Pain Market Barriers

*
Diabetic Neuropathic Pain Appendix

*
Diabetic Neuropathic Pain Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-neuropathic-pain-market-is-projected-to-grow-significantly-by-2034-owing-to-the-launch-of-emerging-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.